Methylphenidate for Treating Tobacco Dependence in Smokers
Author Information
Author(s): Richard D Hurt, Jon O Ebbert, Ivana T Croghan, Darrell R Schroeder, Amit Sood, J Taylor Hays
Primary Institution: Mayo Clinic
Hypothesis
Can methylphenidate help non-ADHD smokers relieve nicotine withdrawal symptoms and promote smoking abstinence?
Conclusion
The study found no evidence that methylphenidate helps smokers quit or reduces withdrawal symptoms.
Supporting Evidence
- Only 10% of the placebo group and 2.5% of the OROS-MPH group achieved smoking abstinence at the end of the medication phase.
- Nicotine withdrawal symptoms did not significantly differ between the treatment groups.
- Adverse events were reported more frequently in the OROS-MPH group compared to placebo.
Takeaway
The study tested a medicine called methylphenidate to see if it could help people stop smoking, but it didn't work.
Methodology
A randomized, double-blind, placebo-controlled, phase II study comparing methylphenidate to placebo over 8 weeks.
Potential Biases
Potential bias due to the high dropout rate and the specific population studied.
Limitations
The study had a high dropout rate and the sample may not represent all smokers.
Participant Demographics
Participants were adult cigarette smokers aged 18 to 65, mostly white, with a mean age of 37.3 years.
Statistical Information
P-Value
p = 0.464 for nicotine withdrawal symptoms, p = 0.786 for the first 14 days post-quit date.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website